Median overall survival (OS) increased from 19.3 months with upfront immune checkpoint inhibition (ICI) to 41.3 months when a ...

During a Case-Based Roundtable® event, Lori J. Wirth, discussed the SELECT trial and the role of multikinase inhibitors in ...

Analysis of Leqembi's commercial potential and market outlook, with a focus on growth projections and investment ...

MI Cancer Seek has received approval from the FDA as a companion diagnostic test to identify those who may benefit from ...

Pharmac has decided to fund lenvatinib from 1 December 2024 for people with some types of thyroid, liver, and kidney cancer. Lenvatinib (branded as Lenvima) stops the number of cancer cells from ...

People with some types of thyroid and liver cancer are getting free access to a targeted treatment for the first time, with ...

Knight Therapeutics Inc. (TSX: GUD) ("Knight" or "the Company"), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial ...